- Home
- LPRO vs ABEO Comparison
LPRO vs ABEO Comparison
Compare LPRO & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | ABEO |
|---|---|---|
| Founded | 2000 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.0M | 320.3M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LPRO | ABEO |
|---|---|---|
| Price | $3.12 | $6.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.58 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 5.1M | 1.2M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 96.46 | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $10.58 | $1,024.31 |
| Revenue Next Year | $14.01 | $145.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $1.18 | $4.00 |
| 52 Week High | $3.13 | $7.54 |
Technical Indicators
Market Signals| Indicator | LPRO | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 74.93 | 65.40 |
| Support Level | $1.28 | $5.24 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 98.62 | 77.62 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is a provider of lending enablement and risk analytics to credit unions, regional banks, finance companies and the captive finance companies of automakers (OEM captive finance companies). Through its flagship product, LPP, its customers, collectively referred to herein as automotive lenders or lenders, make automotive consumer loans to underserved near-prime and non-prime borrowers by harnessing its risk-based interest rate pricing models, powered by its proprietary data and real-time underwriting of automotive loan default insurance coverage from insurers.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.